ISSN:
1432-1041
Keywords:
alprenolol
;
coronary heart disease
;
platelet aggregation
;
fibrinolysis
;
platelet serotonin release
;
exercise
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary In 14 patients with coronary heart disease the effect of long-term treatment (mean 16 months, range 12–33) with alprenolol on platelet function and fibrinolytic activity was studied. While on the beta-blocker and two weeks after gradula withdrawal of it, the patients performed a bicycle-ergometer test and blood samples were obtained before and following exercise. Pre-exercise fibrinolytic activity, assessed by the euglobulin clot lysis time, was 183±27 min (mean ± SEM) while on alprenolol as compared to 111±18 min (p〈0.01) after its withdrawal. Activation of fibrinolysis following exercise was not significantly influenced by alprenolol. In patients treated with alprenolol, the pre-exercise threshold level of ADP, producing platelet aggregation was 3.3 µM (geometric mean) and 5.1 µM after stopping treatment (p≤0.05). In patients receiving the beta-blocker, the ADP- threshold value dropped from 3.3 µM before exercise to 2.3 µM immediately after exercise (not significant). The corresponding values after withdrawal of alprenolol were 5.1 µM and 2.7 µM (p≤0.02). Adrenaline — stimulated aggregation was not significantly influenced by alprenolol. Serotonin release from platelets following maximal ADP- and adrenaline stimuli was not significantly changed by exercise in patients on beta-blockade. After stopping treatment, ADP-induced serotonin release was 22±4.1% before and 15±4.7% after exercise (p〈0.02). The corresponding values using the adrenaline stimulus were 29±5.7% and 17±4.7% (p〈0.05). It is suggested that during physical stress alprenolol may protect platelets against aggregatory stimuli.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00618773
Permalink
